Viridian (VRDN) secures WuXi Biologics pact for long-term veligrotug manufacturing
Rhea-AI Filing Summary
Viridian Therapeutics has signed a Commercial Manufacturing Services Agreement with WuXi Biologics to produce veligrotug drug substance and drug product for commercial use if the therapy is approved. WuXi will act as a non-exclusive supplier, allowing Viridian to use other manufacturers as well.
The deal uses rolling monthly volume forecasts, with a portion becoming a binding purchase commitment, and relies on volume-based pricing. Service fees remain fixed until December 31, 2026, then may be adjusted annually. The agreement runs for an initial five-year term with automatic five-year renewals and includes customary provisions on quality, regulatory compliance, confidentiality, and termination for material breach, insolvency, or certain adverse legal changes.
Positive
- None.
Negative
- None.
Insights
Viridian secures scalable manufacturing for veligrotug under flexible, non-exclusive terms.
Viridian Therapeutics has arranged commercial manufacturing for veligrotug with WuXi Biologics under a five-year, automatically renewable agreement. This covers both drug substance and drug product, creating an operational pathway from potential approval to commercial supply without locking into a single-source dependency.
The contract uses rolling monthly forecasts, where part of each forecast becomes a binding commitment, aligning manufacturing capacity with expected demand while controlling risk. Pricing is volume-based, with service fees fixed through December 31, 2026 before annual adjustments, which may help near-term cost predictability.
Non-exclusivity and termination rights for material breach, insolvency, or certain adverse legal changes provide flexibility if circumstances shift. Future disclosures in periodic reports, including the planned filing of the full agreement with the June 30, 2026 Form 10-Q, may offer more detail on financial impact.
8-K Event Classification
Key Figures
Key Terms
Commercial Manufacturing Services Agreement financial
veligrotug technical
volume-based pricing financial
pass-through costs financial
indemnification financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01 | Entry into a Material Definitive Agreement. |
On May 24, 2026, Viridian Therapeutics, Inc. (the “Company”) entered into a Commercial Manufacturing Services Agreement (the “Agreement”) with WuXi Biologics (Hong Kong) Limited (“WuXi Biologics”) pursuant to which WuXi Biologics will manufacture and supply the Company’s anticipated long-term supply requirements of veligrotug drug substance and drug product for commercial use (the “Product”), if approved. Wuxi Biologics will be a non-exclusive supplier of the Product to the Company and the Company may procure the Product from one or more alternate manufacturers of the Product.
Under the Agreement, the Company will provide rolling forecasts of volume requirements to WuXi Biologics on a monthly basis (each, a “Forecast”). A portion of each Forecast will be considered a binding and non-cancellable commitment of the Company. The parties have agreed to volume-based pricing under the Agreement. The Product service fee will remain fixed until December 31, 2026 and thereafter may be annually adjusted based on a volume-based structure. The Company will also reimburse WuXi Biologics for certain pass-through costs.
The Agreement has an initial term of five years and will automatically renew for successive five-year periods unless either party provides notice of non-renewal at least 24 months prior to the expiration of the initial term or any renewal period. The Company may terminate the Agreement upon 30 days’ prior notice to WuXi Biologics if there is a change in applicable laws that materially and adversely impacts WuXi’s Biologics ability to perform services under the Agreement. Additionally, each party may terminate the Agreement upon an uncured material breach of the Agreement by the other party or upon the other party’s insolvency or bankruptcy.
The Agreement contains customary provisions relating to, among other things, delivery, quality, change procedures, regulatory compliance, confidentiality, dispute resolution, warranties, and indemnification.
The foregoing description of the terms of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement, a copy of which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the period ended June 30, 2026.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Viridian Therapeutics, Inc. | ||||||
| Date: May 26, 2026 | By: | /s/ Stephen Mahoney | ||||
| Stephen Mahoney | ||||||
| President and Chief Executive Officer | ||||||